EGFR+ Lung Cancer | Clinical

Latest Recommendations for Broad Molecular Testing in Advanced NSCLC

September 14, 2022

During a live virtual event, Zofia Piotrowska, MD, MHS, discussed the National Comprehensive Cancer Network guidelines for molecular testing for a patient with advanced non–small cell lung cancer, and how to approach a patient who is found to have an EGFR exon 20 insertion. This is the first of 2 articles based on this event.

Adjuvant Osimertinib Shows 77% Reduction in Disease Recurrence Risk in Early-Stage EGFR-Mutated NSCLC

September 11, 2022

Updated findings from the phase 3 ADAURA trial showed a significant disease-free survival improvement with the use of adjuvant osimertinib compared with placebo in patients with EGFR-mutated, stage I to IIIA non–small cell lung cancer.

Results of Amivantamab and Mobocertinib Trials Evaluated for Use in NSCLC

August 03, 2022

During a Targeted Oncology case-based roundtable event, Christine Bestvina, MD, discussed the outcomes of clinical trials of the EGFR exon 20-targeted agents amivantamab and mobocertinib with participants. This is the second of 2 articles based on this event.